Artigo Revisado por pares

Primary prophylaxis of variceal hemorrhage: A randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate

2002; Elsevier BV; Volume: 123; Issue: 3 Linguagem: Inglês

10.1053/gast.2002.35385

ISSN

1528-0012

Autores

Hock Foong Lui, Adrian J. Stanley, Ewan Forrest, Rajiv Jalan, W.S. Hislop, Peter R. Mills, Niall D. C. Finlayson, A.J. MacGilchrist, Peter C. Hayes,

Tópico(s)

Gastroesophageal reflux and treatments

Resumo

Background & Aims: This randomized controlled trial compared variceal band ligation (VBL), propranolol (PPL), and isosorbide-5-mononitrate (ISMN) in the prevention of first esophageal variceal bleed. Methods: Over a 6-year period, 172 patients with cirrhosis, grade II or III esophageal varices that had never bled, were recruited; 44 into VBL, 66 into PPL, and 62 into ISMN. Baseline patient characteristics: age, 55 ± 11 years; Child–Pugh score, 8 ± 2; 65% alcohol-induced cirrhosis; follow-up period, 19.7 ± 17.6 months (range, 0.13–72.1 months), were comparable in the 3 groups. Results: On intention-to-treat analysis, variceal bleeding occurred in 7% of patients randomized to VBL, 14% to PPL, and 23% to ISMN. The 2-year actuarial risks for first variceal bleed were 6.2% (95% confidence interval [CI], 0.0%–15.0%) for VBL, 19.4% (95% CI, 0.1%–32.4%) for PPL, and 27.7% (95% CI, 14.2%–41.2%) for ISMN. A significant number of patients reported side effects with drug treatment (45% PPL and 42% ISMN vs. 2% VBL; P = 0.00), resulting in withdrawal from treatment in 30% of PPL and 21% of ISMN patients. There were no statistically significant differences in mortality rates in the 3 groups. In as-treated analysis, there was a statistically significant difference in actuarial risk for bleeding at 2 years between VBL and ISMN (7.5%, 95% CI, 2.5%–10.6% vs. 33.0%, 95% CI, 15%–49%, respectively, log rank test P = 0.03) but not between VBL and PPL. Conclusions: VBL was equivalent to PPL and superior to ISMN in preventing first variceal bleed. The side-effect profile for pharmacotherapy was considerable.GASTROENTEROLOGY 2002;123:735-744

Referência(s)
Altmetric
PlumX